These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8794167)

  • 1. Protein engineering and design for drug delivery.
    Murphy JR
    Curr Opin Struct Biol; 1996 Aug; 6(4):541-5. PubMed ID: 8794167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.
    Rogers B; Dong D; Li Z; Li Z
    Curr Pharm Des; 2015; 21(14):1899-907. PubMed ID: 25732550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
    Pardridge WM
    BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
    Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
    Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering better cytokines.
    Steinman L
    Nat Biotechnol; 2003 Nov; 21(11):1293-4. PubMed ID: 14595357
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
    Boado RJ; Zhang Y; Zhang Y; Pardridge WM
    Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.
    Kim NH; Provoda C; Lee KD
    Mol Pharm; 2015 Feb; 12(2):342-50. PubMed ID: 25521817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-Assembled Materials Made from Functional Recombinant Proteins.
    Jang Y; Champion JA
    Acc Chem Res; 2016 Oct; 49(10):2188-2198. PubMed ID: 27677734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells.
    Albarran B; To R; Stayton PS
    Protein Eng Des Sel; 2005 Mar; 18(3):147-52. PubMed ID: 15820981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target Cells.
    Park M; Xu X; Min W; Sugiman-Marangos SN; Beilhartz GL; Adams JJ; Sidhu SS; Grunebaum E; Melnyk RA
    Mol Pharm; 2018 Nov; 15(11):5217-5226. PubMed ID: 30212635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research.
    Dietz GP
    Curr Pharm Biotechnol; 2010 Feb; 11(2):167-74. PubMed ID: 20166965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development.
    Murphy JR
    Cancer Treat Res; 1988; 37():123-40. PubMed ID: 2908622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of recombinant fusion proteins for tissue engineering.
    Nagaoka M; Jiang HL; Hoshiba T; Akaike T; Cho CS
    Ann Biomed Eng; 2010 Mar; 38(3):683-93. PubMed ID: 20131097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silk-based delivery systems of bioactive molecules.
    Numata K; Kaplan DL
    Adv Drug Deliv Rev; 2010 Dec; 62(15):1497-508. PubMed ID: 20298729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of protein fusion on the transition temperature of an environmentally responsive elastin-like polypeptide: a role for surface hydrophobicity?
    Trabbic-Carlson K; Meyer DE; Liu L; Piervincenzi R; Nath N; LaBean T; Chilkoti A
    Protein Eng Des Sel; 2004 Jan; 17(1):57-66. PubMed ID: 14985538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkers for improved cleavage of fusion proteins with an engineered alpha-lytic protease.
    Lien S; Milner SJ; Graham LD; Wallace JC; Francis GL
    Biotechnol Bioeng; 2001 Aug; 74(4):335-43. PubMed ID: 11410858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
    Boado RJ
    Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
    Huang C
    Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.